Development of allergic rhinitis immunotherapy using antigen-loaded small extracellular vesicles

Area of Science:

• Immunology
• Nanotechnology
• Allergy Research

Background:

• Allergic rhinitis results from a Th2-dominant immune response, leading to IgE-mediated symptoms.
• Current treatments aim to rebalance the Th1/Th2 immune response.

Purpose of the Study:

• To investigate the therapeutic potential of small extracellular vesicles (sEVs) for allergic rhinitis treatment.
• To utilize sEVs as carriers for simultaneous delivery of allergens and CpG DNA to modulate immune responses.

Main Methods:

• Prepared sEVs loaded with ovalbumin (OVA) and CpG DNA (CpG-OVA-sEVs).
• Characterized CpG-OVA-sEVs for particle size and zeta potential.
• Administered CpG-OVA-sEVs intranasally in a mouse model of allergic rhinitis.
• Assessed immune response by measuring OVA-specific IgG titers, IgE levels, and allergic symptoms.

Main Results:

• CpG-OVA-sEVs were successfully prepared with an average size of 90 nm.
• sEV uptake and activation of dendritic cells were confirmed.
• Intranasal administration of CpG-OVA-sEVs enhanced OVA-specific IgG titers, indicating a shift towards Th1 response.
• CpG-OVA-sEVs significantly alleviated allergic symptoms and reduced IgE secretion.

Conclusions:

• CpG-OVA-sEVs represent a promising therapeutic strategy for allergic rhinitis.
• This approach effectively rebalances the Th1/Th2 immune response.
• sEVs serve as efficient carriers for co-delivery of allergens and adjuvants.